P

Peptron Inc
KOSDAQ:087010

Watchlist Manager
Peptron Inc
KOSDAQ:087010
Watchlist
Price: 254 000 KRW 6.05% Market Closed
Market Cap: ₩5.9T

Net Margin

-229.1%
Current
Improving
by 283.3%
vs 3-y average of -512.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-229.1%
=
Net Income
₩-14.2B
/
Revenue
₩6.2B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-229.1%
=
Net Income
₩-14.2B
/
Revenue
₩6.2B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Peptron Inc
KOSDAQ:087010
5.9T KRW
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
236.9B USD
Loading...
US
Danaher Corp
NYSE:DHR
165.5B USD
Loading...
CH
Lonza Group AG
SIX:LONN
37.6B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
279.2B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.2B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.8B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.3B EUR
Loading...

Market Distribution

Lower than 96% of companies in Korea
Percentile
4th
Based on 2 632 companies
4th percentile
-229.1%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Peptron Inc
Glance View

Peptron Inc., a biotechnology firm based in South Korea, is weaving a narrative of innovation that marries cutting-edge research with real-world applications. Founded in 1997, the company has carved a niche in the realm of peptide-based pharmaceuticals, focusing on the formulation and delivery of these potent compounds for chronic diseases. Central to its story is the SmartDepot™ technology, a proprietary drug delivery system that ensures precise, sustained release of medication. This technology not only enhances patient compliance by reducing the frequency of dosing but also maximizes therapeutic efficacy, positioning Peptron as a trailblazer in improving patient care. At the heart of Peptron's business model is its ability to capitalize on its advanced drug delivery systems by collaborating with global pharmaceutical giants and seeking strategic partnerships. With a robust pipeline, including promising treatments for Parkinson's disease and various endocrine disorders, Peptron generates revenue through licensing deals, co-development agreements, and the eventual commercialization of its therapeutics. By balancing research innovation with savvy business collaborations, Peptron is not just navigating the competitive biotech landscape; it is rewriting the narrative on harnessing technology for transformative healthcare solutions.

Peptron Inc Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-229.1%
=
Net Income
₩-14.2B
/
Revenue
₩6.2B
What is Peptron Inc's current Net Margin?

The current Net Margin for Peptron Inc is -229.1%, which is above its 3-year median of -512.4%.

How has Net Margin changed over time?

Over the last 3 years, Peptron Inc’s Net Margin has decreased from -219.2% to -229.1%. During this period, it reached a low of -841.2% on Sep 30, 2024 and a high of -219.2% on Aug 30, 2022.

Back to Top